- Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange
- Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO
- Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline
Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (
https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than C$120 million, including the C$34 million raised during the company’s latest equity financing round.
“During the past several months, Cybin has garnered a great deal of attention as an emerging leader in the psychedelic therapeutics space,” said Cybin CEO Doug Drysdale. “We believe the molecules we have under development may have the potential to transform the treatment landscape and fill…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at
https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates
PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit
https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:
https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW?
Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the
InvestorBrandNetwork.